CELZ-201-DDT for the Treatment of Chronic Lower Back Pain
AvailableNCT07137559
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
CELZ-201-DDT is an investigational (experimental) cell therapy currently being studied for people with degenerative disc disease who have chronic lower back pain.
Study details
- Official title
- Expanded Access Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain
- Conditions
- Chronic Back Pain
- Degenerative Disc Disease Lumbar
- Interventions
- Drug: CELZ-201-DDT
- Sponsor
- Creative Medical Technology Holdings Inc
- Sex
- All
- Age range
- from 18 Years to 80 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Confirmed diagnosis of chronic lower back pain due to degenerative disc disease. * No comparable or satisfactory alternative therapy available. Unable to participate in the ongoing CELZ-201-DDT clinical trial. Informed consent provided. Exclusion Criteria: * Any medical condition that poses an unacceptable risk or would interfere with treatment safety or evaluation. * Known hypersensitivity to any component of the investigational product. How to Request Access: * Contact the Expanded Access Coordinator to confirm eligibility and discuss feasibility. * Complete and submit FDA Form 3926 to the appropriate FDA review division. * Obtain IRB review (may be expedited or post-treatment for emergency use). Coordinate drug shipment and treatment schedule.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07137559